Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:46 PM
Ignite Modification Date:
2025-12-24 @ 9:46 PM
NCT ID:
NCT00181532
Eligibility Criteria:
Inclusion Criteria:
* histologically proven non-small cell lung cancer
* UICC stage II-III
* WHO performance status 0-2
* less than 10% weight loss the last 6 month
* in case of previous chemotherapy, radiotherapy may start after a minimum of 21 days after the last chemotherapy course
* reasonable lung function: FEV1\>30% of the predicted value
* no recent(\<3month) severe cardiac disease
* no active peptic ulcer disease
* normal serum bilirubin
* normal serum creatinin
* life expectancy more than 6 month
* measurable cancer
* willing and able to comply with the study prescriptions
* able to give written informed consent before patient registration/randomisation
* no previous radiotherapy to the chest
Exclusion Criteria:
* not not small cell histology, e.g. mesothelioma, lymphoma
* mixed pathology, e.g. non small cell plus small cell cancer
* malignant pleural or pericardial effusion
* concurrent chemotherapy with radiation
* recent (\<3month) myocardial infarction
* uncontrolled infectious disease
* distant metastases (stage IV)
* patients with active peptic ulceration or gastrointestinal bleeding in the last year
* patients with a past history of adverse reaction to NSAIDs
* renal disease
* chronic use of NSAIDs, COX-2 inhibitors or Aspirin in dosis \>120mg/day.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00181532
Study Brief:
Protocol Section:
NCT00181532